In a recent proof-of-concept study, researchers confirmed the feasibility of using CRISPR-armed phages to selectively target clinically-relevant...
Today, Danish company SNIPR Biome announced positive interim clinical results from its Phase 1 clinical trial of SNIPR001, the first CRISPR-armed...
In this post, we introduce our CMN disease overview, which will provide information on all the diseases that are targeted by gene-editing therapies...
SNIPR BIOME, Denmark, announced today that it has dosed the first human subjects in its Phase 1 clinical trial for SNIPR001, an orally administered...
In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...
In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...
In a CRISPR first, scientists in Canada have used bacterial conjugation to deliver a CRISPR system to antibiotic-resistant bacteria in the mouse gut....
Researchers use the M13 bacteriophage to deliver a CRISPR-Cas9 system to Escherichia coli in the mouse gut. The approach marks the first-ever use of...
